m6A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD

Lung adenocarcinoma (LUAD) is the most frequent subtype of lung cancer worldwide. However, the survival rate of LUAD patients remains low. N-6-methyladenosine (m(6)A) and long noncoding RNAs (lncRNAs) play vital roles in the prognostic value and the immunotherapeutic response of LUAD. Thus, discerning lncRNAs associated with m(6)A in LUAD patients is critical. In this study, m(6)A-related lncRNAs were analyzed and obtained by coexpression. Univariate, least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression analyses were conducted to construct an m(6)A-related lncRNA model. Kaplan-Meier analysis, principalcomponent analysis (PCA), functional enrichment annotation, and nomogram were used to analyze the risk model. Finally, the potential immunotherapeutic signatures and drug sensitivity prediction targeting this model were also discussed. The risk model comprising 12 m(6)A-related lncRNAs was identified as an independent predictor of prognoses. By regrouping the patients with this model, we can distinguish between them more effectively in terms of the immunotherapeutic response. Finally, candidate compounds aimed at LUAD subtype differentiation were identified. This risk model based on the m(6)A-based lncRNAs may be promising for the clinical prediction of prognoses and immunotherapeutic responses in LUAD patients.

Automated summary

This study established a risk model for predicting the prognosis and immunotherapeutic response of LUAD patients based on m(6)A-related lncRNAs, which can effectively distinguish patients and fit clinical predictions. The research also identified candidate compounds targeting LUAD subtypes.